524731 Stock Overview
Researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Jenburkt Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,126.95 |
| 52 Week High | ₹1,375.00 |
| 52 Week Low | ₹660.05 |
| Beta | 0.60 |
| 1 Month Change | -7.22% |
| 3 Month Change | 14.16% |
| 1 Year Change | 29.99% |
| 3 Year Change | 87.78% |
| 5 Year Change | 165.38% |
| Change since IPO | 15,772.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524731 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.0% | -3.4% | -1.4% |
| 1Y | 30.0% | 18.6% | 5.8% |
Return vs Industry: 524731 exceeded the Indian Pharmaceuticals industry which returned 18.6% over the past year.
Return vs Market: 524731 exceeded the Indian Market which returned 5.8% over the past year.
Price Volatility
| 524731 volatility | |
|---|---|
| 524731 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 524731's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 524731's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 752 | Ashish Bhuta | jenburkt.com |
Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. It offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. The company offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names.
Jenburkt Pharmaceuticals Limited Fundamentals Summary
| 524731 fundamental statistics | |
|---|---|
| Market cap | ₹4.97b |
| Earnings (TTM) | ₹314.06m |
| Revenue (TTM) | ₹1.49b |
15.8x
P/E Ratio3.3x
P/S RatioIs 524731 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524731 income statement (TTM) | |
|---|---|
| Revenue | ₹1.49b |
| Cost of Revenue | ₹308.94m |
| Gross Profit | ₹1.19b |
| Other Expenses | ₹871.87m |
| Earnings | ₹314.06m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 71.16 |
| Gross Margin | 79.33% |
| Net Profit Margin | 21.01% |
| Debt/Equity Ratio | 1.3% |
How did 524731 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield22%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 23:53 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jenburkt Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |